U.S. Markets open in 15 hrs, 55 mins
| Symbol | Value | Change | Percentage Change |
|---|---|---|---|
| DJIA | 11,288.54 | 73.03 | 0.65% |
| NASDAQ | 2,245.38 | -6.08 | -0.27% |
| S&P 500 | 1,262.90 | 1.38 | 0.11% |
| Day Low 09:30 AM EDT | 72.68 | |
|---|---|---|
| Day High 10:58 AM EDT | 74.58 |
|
| Range | 1.90 | |
| Volume | 2.35 M | |
| 30-Day Avg. Vol. | 2.42 M |
|
| Difference | -2.91% | |
| Market Cap. | 19.52 B | |
| Change | 152.36 M | |
| Shares Out. | 267.31 M | |
| Percent Traded | 0.88% | |
| Revenue | 2.2 B | |
| Earnings | 86.52 M | |
| EPS (TTM) | 0.57 |
| 52-Wk Low 8/20/07 | 58.71 | |
|---|---|---|
| 52-Wk High 1/17/08 | 82.08 |
|
| Range | 23.37 | |
| Prev. Close 7/2/08 | 72.46 | |
| Today's Open | 73.26 | |
| Change | 1.10% | |
| Dividend (TTM) | — | |
| Div. Yield (TTM) | — |
|
| Beta | 0.4128 | |
| P/E Ratio (TTM) | 43.21 | |
| P/E Ratio (Fwd.) | — |
Genzyme makes big money off small-time diseases. The company's product portfolio focuses on rare genetic disorders as well as organ transplant, cancer, and kidney disease. One of its main products, Cerezyme, ... View Full Description
| Earnings/Share(EPS) | Estimate | Actual | Difference |
|---|---|---|---|
| 2 Quarters Ago | 0.925 12/31/07 | 0.91 12/31/07 |
-0.015
Missed
|
| Last Quarter | 0.929 3/31/08 | 0.95 3/31/08 |
0.021
Beat
|
| Quarterly - 06/30/2005 | Annual - 2004 | |
|---|---|---|
| Total Revenue | 668.14 M | 2.20 B |
| Gross Profit | 522.89 M | 1.50 B |
| Operating Income | 164.67 M | 514.00 M |
| Net Income | 123.63 M | 86.53 M |
